Cardiology Today

CHD AND PREVENTION SEAS: Prostate, skin cancers most common among treatment group MUNICH – Although he presented no new data at the European Society of Cardiology’s annual Congress on the SEAS trial, Terje R. Pedersen, MD, released today specific incidents of cancer that patients developed during the four-year trial. The trial results, comparing simvastatin and ezetimibe (Vytorin, Merck) in aortic stenosis with placebo, were first announced in July during a press conference. Results Pedersen, professor at the Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway, said the drug showed no benefit in patients ... FULL STORY

CHD AND PREVENTION

SEAS: Prostate, skin cancers most common among treatment group

MUNICH – Although he presented no new data at the European Society of Cardiology’s annual Congress on the SEAS trial, Terje R. Pedersen, MD, released today specific incidents of cancer that patients developed during the four-year trial.

The trial results, comparing simvastatin and ezetimibe (Vytorin, Merck) in aortic stenosis with placebo, were first announced in July during a press conference.

Results

Pedersen, professor at the Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway, said the drug showed no benefit in patients ...
FULL STORY

December 10, 2008 EUROECHO 12th Annual Meeting of the European Association of Echocardiography Lyon, France more information>>
December 7, 2008 Innovations in Cardiovascular Interventions Tel Aviv, Israel more information>>
December 3, 2008 7th International Course on Carotid Angioplasty and Other Crebrovascular Interventions Frankfurt, Germany more information>>

December 10, 2008
EUROECHO 12th Annual Meeting of the European Association of Echocardiography
Lyon, France
more information>>

December 7, 2008
Innovations in Cardiovascular Interventions
Tel Aviv, Israel
more information>>

December 3, 2008
7th International Course on Carotid Angioplasty and Other Crebrovascular Interventions
Frankfurt, Germany
more information>>

See complete calendar listings. »

QUOTE OF THE WEEK "...the report does not seem to recognize that there are huge benefits to medical imaging...." Click here to read full article.

QUOTE OF THE WEEK

"...the report does not seem to recognize that there are huge benefits to medical imaging...."

Click here to read full article.

VASCULAR MEDICINE/INTERVENTION Managing high-risk patients with ARBs Initial results from the ONTARGET study confirm that telmisartan, an angiotensin receptor blocker, is a viable option for patients with vascular disease or high-risk diabetes. This is the first time that an ARB has been shown to be as efficacious as the established angiotensin-converting enzyme inhibitor for reduction of CVD risk in a broad population of patients with underlying vascular disease or diabetes with evidence of end-organ damage. Telmisartan had a favorable safety profile in comparison with ramipril, the “gold standard” ACE, in this patient population. Researchers enrol... FULL STORY

VASCULAR MEDICINE/INTERVENTION

Managing high-risk patients with ARBs

Initial results from the ONTARGET study confirm that telmisartan, an angiotensin receptor blocker, is a viable option for patients with vascular disease or high-risk diabetes. This is the first time that an ARB has been shown to be as efficacious as the established angiotensin-converting enzyme inhibitor for reduction of CVD risk in a broad population of patients with underlying vascular disease or diabetes with evidence of end-organ damage. Telmisartan had a favorable safety profile in comparison with ramipril, the “gold standard” ACE, in this patient population. Researchers enrol...

FULL STORY